Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
31
TOVX Quote, Financials, Valuation and Earnings
Last price:
$0.20
Seasonality move
:
6900.27%
Day range:
$0.18 - $0.20
52-week range:
$0.16 - $1.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.33x
P/B ratio:
1.00x
Volume:
2.7M
Avg. volume:
12.2M
1-year change:
-85.71%
Market cap:
$6.7M
Revenue:
--
EPS (TTM):
-$5.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -86.49% | $7.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.80 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835M | $0.56 | 4.94% | 9.32% | $88.17 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TOVX
Theriva Biologics, Inc.
|
$0.20 | $7.00 | $6.7M | -- | $0.00 | 0% | 0.33x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.56 | $31.80 | $4.2B | 10.73x | $0.00 | 0% | 3.89x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$332.92 | $457.00 | $44.2B | 147.50x | $0.00 | 0% | 11.97x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$61.73 | $88.17 | $11.9B | 34.65x | $0.00 | 0% | 3.70x |
|
IMNN
Imunon, Inc.
|
$3.25 | $21.50 | $6.9M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$6.02 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.255 | 66.16% | 0.68x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.788 | 5.63% | 3.25x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.412 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -2.483 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Theriva Biologics, Inc. vs. Competitors
-
Which has Higher Returns TOVX or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Theriva Biologics, Inc.'s net margin of 96.33%. Theriva Biologics, Inc.'s return on equity of -171.04% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About TOVX or ACAD?
Theriva Biologics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 3400%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 29.48%. Given that Theriva Biologics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TOVXTheriva Biologics, Inc.1 1 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is TOVX or ACAD More Risky?
Theriva Biologics, Inc. has a beta of 0.535, which suggesting that the stock is 46.463% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock TOVX or ACAD?
Theriva Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TOVX or ACAD?
Theriva Biologics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Theriva Biologics, Inc.'s net income of -$4.4M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Theriva Biologics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics, Inc. is 0.33x versus 3.89x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M ACADACADIA Pharmaceuticals, Inc.3.89x 10.73x $284M $273.6M
-
Which has Higher Returns TOVX or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Theriva Biologics, Inc.'s net margin of 16.99%. Theriva Biologics, Inc.'s return on equity of -171.04% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About TOVX or ALNY?
Theriva Biologics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 3400%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.27%. Given that Theriva Biologics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TOVXTheriva Biologics, Inc.1 1 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is TOVX or ALNY More Risky?
Theriva Biologics, Inc. has a beta of 0.535, which suggesting that the stock is 46.463% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock TOVX or ALNY?
Theriva Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TOVX or ALNY?
Theriva Biologics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Theriva Biologics, Inc.'s net income of -$4.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Theriva Biologics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics, Inc. is 0.33x versus 11.97x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M ALNYAlnylam Pharmaceuticals, Inc.11.97x 147.50x $1.1B $186.4M
-
Which has Higher Returns TOVX or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Theriva Biologics, Inc.'s net margin of -5.2%. Theriva Biologics, Inc.'s return on equity of -171.04% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About TOVX or BMRN?
Theriva Biologics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 3400%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.17 which suggests that it could grow by 42.84%. Given that Theriva Biologics, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Theriva Biologics, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TOVXTheriva Biologics, Inc.1 1 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is TOVX or BMRN More Risky?
Theriva Biologics, Inc. has a beta of 0.535, which suggesting that the stock is 46.463% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.248, suggesting its less volatile than the S&P 500 by 75.229%.
-
Which is a Better Dividend Stock TOVX or BMRN?
Theriva Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TOVX or BMRN?
Theriva Biologics, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. Theriva Biologics, Inc.'s net income of -$4.4M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Theriva Biologics, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics, Inc. is 0.33x versus 3.70x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M BMRNBioMarin Pharmaceutical, Inc.3.70x 34.65x $895M -$46.6M
-
Which has Higher Returns TOVX or IMNN?
Imunon, Inc. has a net margin of -- compared to Theriva Biologics, Inc.'s net margin of --. Theriva Biologics, Inc.'s return on equity of -171.04% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About TOVX or IMNN?
Theriva Biologics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 3400%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 561.54%. Given that Theriva Biologics, Inc. has higher upside potential than Imunon, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Imunon, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TOVXTheriva Biologics, Inc.1 1 0 IMNNImunon, Inc.3 1 0 -
Is TOVX or IMNN More Risky?
Theriva Biologics, Inc. has a beta of 0.535, which suggesting that the stock is 46.463% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.057, suggesting its more volatile than the S&P 500 by 105.729%.
-
Which is a Better Dividend Stock TOVX or IMNN?
Theriva Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TOVX or IMNN?
Theriva Biologics, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. Theriva Biologics, Inc.'s net income of -$4.4M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, Theriva Biologics, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics, Inc. is 0.33x versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns TOVX or SVRA?
Savara, Inc. has a net margin of -- compared to Theriva Biologics, Inc.'s net margin of --. Theriva Biologics, Inc.'s return on equity of -171.04% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About TOVX or SVRA?
Theriva Biologics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 3400%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 79.61%. Given that Theriva Biologics, Inc. has higher upside potential than Savara, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TOVXTheriva Biologics, Inc.1 1 0 SVRASavara, Inc.6 0 0 -
Is TOVX or SVRA More Risky?
Theriva Biologics, Inc. has a beta of 0.535, which suggesting that the stock is 46.463% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.
-
Which is a Better Dividend Stock TOVX or SVRA?
Theriva Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TOVX or SVRA?
Theriva Biologics, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Theriva Biologics, Inc.'s net income of -$4.4M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Theriva Biologics, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics, Inc. is 0.33x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
